CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 562 enrolled
Drug / intervention
EHR Nudgeother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05590962
NCT05590962N/ACompleted

Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer

Abramson Cancer Center at Penn Medicine·interventional·Posted Oct 21, 2022·Updated Feb 6, 2025

In Brief

A clinical study evaluating EHR Nudge for Cancer. Completed, enrolled 562 participants across 1 site.

Detailed Summary

Patients with advanced cancer suffer from high symptom burden and aggressive end-of-life care. Early specialty palliative care is an evidence-based practice that improves symptom burden, quality of life, and survival in advanced cancer. However, over half of patients with advanced cancer die before receiving palliative care. Clinician-level biases and suboptimal identification of high-risk patients are major barriers to palliative care uptake. In this 2-arm pragmatic clinical trial, the investigators will randomize practices within a large community oncology network to receive an intervention consisting of algorithm-based default palliative care referrals. The investigators will study the impact of such an intervention on palliative care utilization and end-of-life outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States

Timeline

N/ACompletedFinished
2023202420252026
First PostedOct 21, 2022
Enrollment StartNov 9, 2022
Primary CompletionJun 13, 2023
Study CompletionOct 3, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.7 years ago

Interventions

EHR Nudgeother

Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.